Biological E gets DGCA nod to begin the next phase of trials for its COVID-19 vaccine

This vaccine candidate includes an antigen that was in-licensed from BCM Ventures, which is an integrated commercialisation team of Baylor College of Medicine in Houston, and an advanced adjuvant from the US-based vaccine focused pharmaceutical firm Dynavax Technologies Corporation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3pCcb71
via IFTTT